论文部分内容阅读
目的:旨在探讨血清脂肪因子chemerin水平与代谢综合征患者合并冠心病的相关性。方法:共纳入116名代谢综合征患者,将所有患者分为两组,合并冠心病组(CAD+,n=47)及未合并冠心病组(CAD-,n=69),使用酶联免疫吸附(ELISA)法测量每组血清的血清chemerin水平。结果:CAD+组患者的血清chemerin水平较CAD-组患者显著升高(129.83±29.18 vs 94.01±23.54 ng/mL;P<0.01),多元Logistic回归分析结果显示血清chemerin水平与代谢综合征患者合并冠心病存在独立相关性(优势比1.565,95%可信区间1.104-2.876;P<0.05)。结论:血清chemerin水平是代谢综合征患者合并冠心病的独立危险因子,血清chemerin可能是预测代谢综合征患者发生冠心病风险的重要的生物学标记物。
Objective: To investigate the relationship between serum chemerin level and coronary heart disease in patients with metabolic syndrome. Methods: A total of 116 patients with metabolic syndrome were enrolled in this study. All patients were divided into two groups: CAD group (CAD +, n = 47) and CAD group (CAD-, n = 69) (ELISA) method to measure serum chemerin level in each group. Results: The level of chemerin in CAD + patients was significantly higher than that in CAD-patients (129.83 ± 29.18 vs 94.01 ± 23.54 ng / mL; P <0.01). The results of multivariate Logistic regression analysis showed that serum chemerin was associated with metabolic syndrome Heart disease was independently associated (odds ratio 1.565, 95% confidence interval 1.104-2.876; P <0.05). Conclusion: Chemerin level is an independent risk factor for CAD in patients with CHD. Serum chemerin may be an important biomarker for predicting the risk of coronary heart disease in patients with metabolic syndrome.